International Society of Nephrology first consensus guidance for preclinical animal studies in translational nephrology

• Published in: Kidney international Vol. 104; no. 1; pp. 36 - 45
• Main Authors: Nangaku, Masaomi, Kitching, A. Richard, Boor, Peter, Fornoni, Alessia, Floege, Jürgen, Coates, P. Toby, Himmelfarb, Jonathan, Lennon, Rachel, Anders, Hans-Joachim, Humphreys, Benjamin D., Caskey, Fergus J., Fogo, Agnes B., Angeletti, Andrea, Bedard, Patricia W., Benigni, Ariela, Granqvist, Anna Björnson, Chabova, Vera Certikova, Chatziantoniou, Christos, Cross, Jennifer, Damster, Sandrine, Donner, Jo-Ann, Eitner, Frank, Faguer, Stanislas, Fontanella, Antonio, Fujimoto, Yuri, Gaut, Joseph, Gewin, Leslie, Hansen, Pernille B.L., He, John Cijiang, Hughes, Jeremy, Inagi, Reiko, Jenkinson, Celia, Jha, Vivekanand, Kato, Mikio, Kelly, Darren, Kopp, Jeffrey, Korstanje, Ron, Mačiulaitis, Romaldas, Mark, Patrick B., Marti, Hans-Peter, McAdoo, Stephen P., Miner, Jeffrey H., Ortiz, Alberto, Parikh, Samir M., Pozzi, Ambra, Romagnani, Paola, Ronco, Pierre, Rovin, Brad H., Saez-Rodriguez, Julio, Saleem, Moin A., Sayer, John A., Shankland, Stuart, Shaw, Andrey S., Soler Romeo, Maria José, Suzuki, Yusuke, Takano, Tomoko, Tang, Sydney, Tolba, Rene, Viel, John, Yamada, Yoshihisa, Yanagita, Motoko, Yokoo, Takashi, Yoshida, Nobuya, Yuen, Darren, Zent, Roy, Zhang, Aihua
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.07.2023
• Subjects: Animals; CKD; Consensus; drug development; ISN; kidney; Kidney Diseases - drug therapy; Nephrology; Quality of Life; Societies, Medical; drug development; kidney; ISN; CKD
• ISSN: 0085-2538; 1523-1755
• DOI: 10.1016/j.kint.2023.03.007

Preclinical tests in animal models are key steps in early drug development. Consequently, the International Society of Nephrology held a consensus meeting that connected experts in the global kidney community in order to provide guidance on optimal management of translational animal studies for the development of new drugs to treat kidney disease, entitled “TRANSFORM; TRAnslational Nephrology Science FOR new Medications.” The meeting covered various themes, including the following: (i) selection of disease model; (ii) pharmacokinetics; (iii) interventions in late preclinical models; (iv) choice of animal; (v) statistical power; (vi) organoids and organ-on-a-chip models; and (vii) reporting of results. This guidance is the first to be provided on the optimal conduct of translational animal studies for the development of new drugs to treat kidney disease. These recommendations are designed to accelerate development of new drugs for efficacious treatment of kidney diseases, and to improve the prognosis and quality of life of patients with a variety of kidney diseases.